Effects of empagliflozin on glycemic control, insulin, C-peptide, and mannose levels
Baseline concentrations of fasting and post-load glycaemic variables, i.e., glucose, insulin, proinsulin and C-peptide, did not differ between the two groups, while mannose levels were slightly higher in the empagliflozin group compared to placebo (92.7 vs. 86.1 µmol/L, p = 0.04; Supplemental Table After seven months of treatment, fasting plasma glucose (FPG), 2-hour post-load glucose (2hPG) and 2-hour post-load insulin were significantly reduced by empagliflozin compared with placebo, a difference no longer visible three months after drug cessation (Figs. 